vated in the brains of infected individuals, including CXCL12. Entry of these cells leads to viral reservoirs, neuroinflammation, and neuronal damage. These may eventually lead to HIV-associated neurocognitive disorders. Although antiretroviral therapy (ART) has significantly improved the lives of HIV-infected people, the prevalence of cognitive deficits remains unchanged despite ART, still affecting .50% of infected individuals. There are no therapies to reduce these deficits or to prevent CNS entry of CD14 + CD16 + monocytes. The goal of this study was to determine whether CXCR7, a receptor for CXCL12, is expressed on CD14 + CD16 + monocytes and whether a small molecule CXCR7 antagonist (CCX771) can prevent CD14 + CD16 + monocyte transmigration into the CNS.
We showed for the first time that CXCR7 is on CD14 + CD16 + monocytes and that it may be a thera- 
Introduction
HIV enters the CNS within 4-8 d after peripheral infection [1, 2] , ultimately contributing to cognitive deficits in 40-70% of infected individuals [3] [4] [5] . These deficits develop despite ART and regardless of viral load [5] [6] [7] . They are mediated, in part, by transmigration of monocytes across the BBB into the CNS [3, [8] [9] [10] . HIV-infected, as well as uninfected, monocytes transmigrate into the CNS in response to chemokines [11] [12] [13] [14] . Once within the CNS, these monocytes elaborate additional inflammatory mediators, viral proteins, and virus and may also differentiate into macrophages that contribute to the initial establishment and continued seeding of viral reservoirs within the brain [15] [16] [17] . These processes lead to infection of other CNS cell types, neuroinflammation, and neuronal damage that even in the presence of ART, may result in cognitive deficits [18] [19] [20] [21] .
Monocytes are heterogeneous and are distinguished based on their surface CD14 (the LPS receptor) and CD16 (the FcgIIIR) [22] . The majority of monocytes in healthy people are classic CD14 + CD16 2 monocytes, whereas 5-10% of monocytes are mature and are CD14 + CD16 + [23] . CD14 + CD16 + monocytes are key to the inflammatory response and during HIV infection, are significantly increased in the peripheral blood, comprising 20-60% of monocytes in infected individuals despite successful ART [23] [24] [25] . In addition, CD14 + CD16
+ monocytes are susceptible to HIV infection [17, 26] and are found in the CNS of HIVinfected people [12, 13] . Thus, these cells are proposed to facilitate HIV entry into the CNS, contributing to the processes that lead to HIV-associated neurocognitive disorders [3, 23] . CD14 + CD16 + monocytes transmigrate across the BBB in response to chemokines, such as CCL2 and CXCL12, which are each elevated in the brains of HIV-infected individuals [3, 8, [27] [28] [29] [30] . CXCL12 is also expressed constitutively in the CNS and among many other functions, mediates T cell infiltration [31] [32] [33] . Our laboratory showed that CXCL12 induces the transmigration of CD14 + CD16
+ monocytes across an in vitro human BBB model [27] . Leukocyte migration to CXCL12 was believed to be solely mediated by chemokine receptor CXCR4 until the identification of another CXCL12 receptor, the atypical chemokine receptor 3 (CXCR7) [34] . With the use of the CXCR7 antagonist CCX771 and the CXCR4 antagonist AMD3100, several studies showed that CXCR7 scavenges excess CXCL12 to enable cell movement or found that CXCR7 directly mediates cell migration [31, [35] [36] [37] . CXCR7 is similar in structure to CXCR4, although CXCR7 signals through b-arrestin recruitment and MAPK activation rather than through conventional G protein signaling [35, 38, 39] . The expression of CXCR7 on different leukocyte subsets was unclear, and the role of CXCR7 in monocyte transmigration was undetermined [31, 34, [40] [41] [42] . Two studies reported CXCR7 on human monocytes, but another study showed that CXCR7 was not detectable on these cells [41, 43, 44] . These studies examined CXCR7 on the total population of peripheral blood monocytes; however, its expression and function had not been determined on mature CD14 + CD16 + monocytes. As CD14 + CD16 + monocytes are increased in the peripheral blood in HIV infection and in many inflammatory disorders [45] and enter the CNS [12, 13] , it is essential to understand the potential involvement of CXCR7 in the transmigration of mature CD14 +
CD16
+ monocytes across the BBB.
In this study, we show that CXCR7 is expressed on CD14 2 monocytes. We also showed that the CXCR7 antagonist CCX771 blocks specifically CD14 + CD16 + monocytes from transmigration across the BBB, suggesting that it will reduce their entry into the CNS, thereby reducing HIV infection of the brain. We propose that CXCR7 is a potential therapeutic target to reduce inflammation in HIV-associated neurocognitive disorders and that it may also be a therapeutic target for other inflammatory disorders in which CD14 +
+ monocytes contribute to pathogenesis.
MATERIALS AND METHODS

Materials
The CXCR7-specific antagonist CCX771 was obtained from ChemoCentryx (Mountain View, CA, USA), CXCR4 antagonist AMD3100 was from SigmaAldrich (St. Louis, MO, USA), and CXCL12 from R&D Systems (Minneapolis, MN, USA). Cells were pretreated with 10 mM CCX771, 10 mM AMD3100, or DMSO (diluent) for 20 min before functional assays. [8, 26] . Blood from ART-treated, HIV-seropositive people from the MHBB and WIHS (Bronx location) was obtained. Patients gave written, informed consent for the provision of blood for the purposes of research. The Institutional Review Board at Montefiore Medical Center, Albert Einstein College of Medicine, and the Mount Sinai Program for the Protection of Human Subjects Institutional Review Board approved the protocols under which these samples were obtained. Demographics and virologic characteristics of individuals from the 2 cohorts are in Table 1 . PBMCs were isolated within 2-4 h of blood draw, phenotyped by flow cytometry, and also used for transmigration assays.
Cell isolation and culture
Flow cytometry
Analysis was performed on PBMCs using antibodies specific for human CD14 (Clone M5E2), CD16 (Clone 3G8), and CD3 (Clone HIT3a; BD Biosciences, San Jose, CA, USA); CXCR7-PE (Clone 11G8; 0.3-0.45 mg/test depending on the lot; R&D Systems); and CXCR4-PE (Clone 12G5; 0.3 mg/test; eBioscience, San Diego, CA, USA) or isotype-matched control antibodies. CXCR7 and CXCR4 antibodies were titered to determine optimal staining conditions, and CD14, CD16, and CD3 were previously titered and optimized depending on the fluorophore used. Cells (2 3 10 5 in 100 ml) were stained in the dark on ice for 30 min, washed once, and fixed with 2% paraformaldehyde in 13 PBS. At least 10,000 monocytes or T cells were acquired with the BD FACSCanto II flow cytometer. Forward-and side-scatter and CD14-and CD3-positive signal based on isotype-matched control staining were used to gate on monocytes and T cells, respectively. Forward-scatter area vs. forward-scatter height was used to gate on single cells. Analysis was performed using FlowJo software (v. 10.0.8; Tree Star, Ashland, OR, USA). MFI for CXCR7 and CXCR4 was calculated after subtracting the MFI of the isotype-matched control antibody.
Antibody adsorption assay
MCF-7 cells (2 3 10 6 ), a human breast cancer cell line of epithelial cells derived from metastatic mammary gland tissue that expresses surface CXCR7 [46] , were resuspended in 13 PBS with 1% BSA. Cells were incubated for 1 h at room temperature with CXCR7 antibody at 23 the concentration normally used for flow cytometry staining. After 1 h, cells were spun, and the unbound antibody in the supernatant was collected. This was repeated one more time. MCF-7 cells and mature CD14 + CD16 + monocytes were then stained with the remaining unbound CXCR7 antibody in the supernatant (the adsorbed antibody) and acquired and analyzed as described in Flow cytometry above.
Human BBB model
The BBB model consists of human BMVECs (Applied Cell Biology Research Institute, Kirkland, WA, USA) and human cortical astrocytes isolated from tissue as part of an approved research protocol at the Albert Einstein College of Medicine. BMVECs and astrocytes were cocultured on opposite sides of a gelatin-coated tissue-culture insert with 3 mm pores (BD Falcon; Becton Dickinson, Franklin Lakes, NJ, USA), as described previously [8, 11] . In brief, astrocytes were seeded on the basolateral side (CNS side) of the insert and BMVECs added to the apical side (peripheral blood side). Cocultures were grown to confluence for 3 d, at which time, astrocytic foot processes penetrate the insert and contact the BMVEC layer to induce BBB properties, including impermeability to albumin [8, 11] .
BBB transmigration assay
BBB coculture inserts were placed in wells of a 24-well plate, with BSA (vehicle) or CXCL12 (R&D Systems) added to the wells on the basolateral side of the inserts (bottom). For BBB transmigration experiments that included the antagonists, PBMCs were treated with DMSO (diluent), CCX771 (10 mM), or AMD3100 (10 mM) for 20 min before the transmigration assay. PBMCs (4 3 10
5
) were then added to the apical side of the coculture inserts (top). Each transmigration condition was assayed with 4 replicate inserts. After 24 h, the transmigrated cells were collected from the bottom of the wells on the basolateral side of the inserts. Collected cells were stained for human CD14 (Clone M5E2), CD16 (Clone 3G8), and CD3 (Clone HIT3a; BD Biosciences); fixed with 2% paraformaldehyde; and quantified by flow cytometry. The number of each leukocyte subset that transmigrated was determined and quantified, or the percent of each subset that transmigrated was determined relative to the total absolute cell number of that subset (i.e., the percent of cells relative to their input).
The optimal transmigration duration and CXCL12 concentration were determined by kinetic and dose response analysis, respectively. Transmigration assays with cells from HIV-infected individuals were performed with cells from individuals from the WIHS cohort, as we did not receive enough blood to perform these assays with cells from the MHBB cohort.
Chemotaxis assay
Directed cell movement was assayed using a 48-well microchemotaxis chamber (Neuro Probe, Gaithersburg, MD, USA), as we performed previously [8, 47] . ) were resuspended in chemotaxis medium (RPMI 1640, supplemented with 10% FBS) in the presence of CCX771 (10 mM) or DMSO (diluent) and incubated at 37°C for 20 min. Cells were then placed in the upper wells of the microchemotaxis chamber, separated from the lower wells by a polycarbonate filter with 5 mm pores (Neuro Probe). The lower wells of the microchemotaxis chamber contained chemotaxis medium alone or CXCL12 (5 ng/ml) resuspended in chemotaxis media. Duplicate chambers were incubated at 37°C with 5% CO 2 for 30 or 60 min to enable cell chemotaxis. The filters were then removed, fixed, and stained using the Siemens Diff Quick Stain Set (Thermo Fisher Scientific, Waltham, MA, USA). Migrated cells were quantified using densitometry with the computer imaging software UN-SCAN-IT (Silk Scientific, Orem, UT, USA). Two time points were examined for each experiment, as the response to CXCL12 varies widely with primary human cells. The maximal fold change of the 30 and 60 min time points was determined for each experiment, and the time point with the strongest response to CXCL12 for each experiment was included in the final quantification and graph.
Statistical analysis
Statistical analyses were performed using Prism 6.0g (GraphPad Software, San Diego, CA, USA). Mann-Whitney U tests were used for paired nonparametric measures and Wilcoxon for nonpaired, nonparametric measures. Measures with P , 0.05 were considered statistically significant.
RESULTS
CD14 +
CD16
+ monocytes transmigrate preferentially across the BBB in response to CXCL12 compared with CD14 + CD16
2 monocytes or T cells CXCL12 is expressed constitutively in the CNS and is increased in the brains of HIV-infected individuals with CNS pathology [29, 30, [48] [49] [50] . We [8, 23] and others [13, 24, 51] showed that CD14 + CD16 + monocytes are significantly increased in the peripheral blood of HIV-infected individuals and that these cells are key mediators of HIV CNS pathogenesis. However, transmigration across the BBB of different monocyte populations in response to CXCL12 had not been characterized extensively. We examined CXCL12-mediated transmigration of the CD14 + CD16 + and CD14 + CD16 2 monocyte subsets using a human BBB model. As CXCL12 is known to be a potent T cell chemoattractant [31] [32] [33] , we also examined transmigration of unstimulated T cells. We added freshly isolated PBMCs obtained from HIV-negative individuals to the top of the in vitro model of the human BBB (Fig. 1A) . Cells were allowed to transmigrate in response to different concentrations of CXCL12 for 24 h, and the input population was analyzed using flow cytometry (FACS). Monocytes and lymphocytes were identified using forward-and sidescatter. Monocyte subsets were then analyzed by CD14 and CD16 expression (Fig. 1B) 5 /insert) were added to the apical side of BBB inserts ("periphery") and CXCL12 to the bottom of the wells on the basolateral side of the inserts ("CNS"). Cells were allowed to transmigrate across the BBB in response to CXCL12 for 24 h, after which cells in the bottom of the wells were collected, analyzed, and counted by FACS. (B) PBMCs from HIV-negative individuals were stained with CD14-allophycocyanin-and CD16-PE-coupled antibodies. Forward (FSC-A)-and side-scatter area (SSC-A) were used to determine monocyte and lymphocyte gating. CD14 and CD16 were then used to identify CD14 + CD16 + and CD14 + monocytes would transmigrate in response to the low levels of CXCL12 that are present during basal homeostatic conditions in the CNS [49, 50] , which may contribute to early infection of the CNS.
CD14
+ CD16 + monocytes express CXCR7
To determine whether CXCR7 participates in CXCL12-induced transmigration across the BBB of CD14 + CD16 + monocytes, we first examined surface CXCR7 and CXCR4 on monocytes from healthy individuals. Studies from other groups had evaluated CXCR7 on the total population of freshly isolated monocytes that are 90-95% CD14 + CD16
2 monocytes [23] . Whereas 2 of these studies found CXCR7 to be minimally expressed on monocytes [43, 44] , another group demonstrated that the total population of monocytes does not express CXCR7. This group also showed, using a CXCR7-transfected human breast cancer cell line, that only the CXCR7 antibody from Clone 11G8 specifically detects CXCR7 [41] . We examined receptor expression on CD14 + CD16 + and CD14 + CD16 2 monocytes using the CXCR7 (11G8 clone)
antibody that others showed to be specific [41] . We confirmed this specificity using an antibody adsorption assay, as described in Materials and Methods and in Supplemental Fig. 1 . PBMCs were isolated from fresh whole blood from healthy people; stained for CD14, CD16, and CXCR7 or CXCR4; and analyzed by FACS. Monocyte subsets were identified by their CD14 and CD16 expression (Fig. 1B) . Surface CXCR7 and CXCR4 were determined on both monocyte subsets by subtracting the IgG isotype-matched control MFI from the CXCR7 or CXCR4 MFI ( Fig. 2A and B 2D ), showing that its expression is generally relatively equivalent on both monocyte subsets in PBMCs from healthy people. This is in agreement with some studies [52, 53] but in contrast with a few others that found that CXCR4 on the CD16 + subset was either decreased [17, 54] 2 monocytes, and CD3 + T cells using PBMCs isolated from HIV-negative individuals. Freshly isolated PBMCs were pretreated for 20 min with DMSO (diluent), 10 mM CCX771 (CXCR7 antagonist), or 10 mM AMD3100 (CXCR4 antagonist) added to the human BBB model and allowed to transmigrate in response to BSA (vehicle) or CXCL12 (25 ng/ml) for 24 h. Transmigrated cells were recovered from the bottom of the wells, stained for CD14, CD16 and CD3, and analyzed by FACS to quantify absolute cell numbers.
CXCL12 induced significant transmigration across the BBB for all cell types compared with vehicle (Fig. 3) . Transmigration across the BBB of CD14 + CD16
+ monocytes was blocked by CCX771, whereas their transmigration was not reduced by AMD3100 (Fig. 3A) . In contrast, CD14 + CD16 2 monocyte transmigration was not blocked by CCX771 but was reduced significantly by AMD3100 (Fig. 3B) As CD14 + CD16 + monocytes are preferentially infected and are key to HIV-associated cognitive deficits, these data indicate the importance in characterizing CXCR7 as a target to block CNS entry of specifically CD14 + CD16 + monocytes. CCX771 reduced CXCL12-mediated transmigration of unstimulated T cells, although their transmigration remained significantly higher than baseline. Unstimulated T cells were shown previously to respond to CXCL12 through CXCR4 [56, 57] , and in our assay, their transmigration was blocked significantly to below baseline by AMD3100 (Fig. 3C ). This suggests that whereas CXCR7 may contribute minimally to the transmigration of T cells to CXCL12, their transmigration is mainly mediated by CXCR4.
Monocytes matured in vitro with M-CSF express CXCR7
The endothelial cells of the BBB express CXCR7, which regulates the presentation of CXCL12 on the BBB [31] . In a publication from another group, CCX771 did not affect CXCL12 presentation or block CXCR7 on HUVECs when it was used to examine the role of CXCR7 in transendothelial migration of cancer cells [58] . Based on these findings, we did not expect endothelial cell CXCR7 to affect our monocyte transmigration studies. However, to exclude a potential effect of CCX771 on endothelial CXCR7/CXCL12 and to examine the role of CXCR7 in CD14 + CD16 + monocyte migration in the absence of endothelial cells, we used an in vitro monocyte maturation system, as described previously [8, 26] . We use this monocyte maturation system to obtain sufficiently high numbers of primarily CD14 + CD16 + monocytes, such that we are able to examine chemotaxis, as total monocytes from healthy individuals only contain 5-10% CD14 + CD16 + monocytes, which would not enable us to determine specifically the effect of CCX771 on that population. In brief, for monocyte maturation in culture, we obtained freshly isolated CD14 + monocytes from PBMCs of HIV-negative individuals using Ficoll-Paque density gradient centrifugation and immunomagnetic CD14-positive selection. The CD14 + cells were then cultured nonadherently in Teflon-coated flasks in the presence of M-CSF to obtain large numbers of mature CD14 + CD16 + monocytes (Fig. 4A) . PBMCs from HIV-negative individuals were pretreated with diluent, 10 mM CCX771, or 10 mM AMD3100 for 20 min before being added to the BBB model and allowed to transmigrate to 25 ng/ml CXCL12 for 24 h. PBMCs were stained with CD14, CD16, and CD3, and transmigrated cells were collected from the bottom of the wells and analyzed by FACS. The number of (A) CD14 + CD16 + monocytes, (B) CD14 + CD16 2 monocytes, and (C) CD3 + T cells that transmigrated across the BBB was quantified. DMSO was used as a diluent and control. Transmigrations were performed with PBMCs from 10 independent donors, except for AMD3100 (n = 6). Data are represented as means 6 SEM. Significance was determined by Wilcoxon signed-rank test. Significance is compared with baseline unless indicated otherwise. *P , 0.05; **P , 0.01. N.S., Nonsignificant.
upper wells of the chamber. Mature CD14 + CD16 + monocytes were pretreated for 20 min with diluent or 10 mM CCX771 before adding the cells to the chemotaxis chamber. CCX771 significantly reduced CXCL12-mediated chemotaxis of CD14 + CD16 + monocytes (Fig. 4D ). This indicates that CXCR7 contributes to CD14 + CD16 + monocyte migration in response to CXCL12.
CXCR7 is increased on CD14 + CD16 + monocytes from PBMCs of HIV-infected individuals
We used cells from HIV-negative people to show for the first time that CXCR7 is expressed on CD14 + CD16 + monocytes and that it mediates their transmigration and chemotactic response to CXCL12. To determine whether CXCR7 can be a therapeutic !target for disease, we focused on the role of CXCR7 on CD14 + CD16 + monocytes from individuals with HIV. CD14 + CD16 + monocytes are increased significantly in the periphery of HIV-infected people and are key mediators of HIV-associated cognitive deficits despite ART. In addition, CD14 + CD16 + monocytes comprise the major monocyte subset that is HIV infected, and this monocyte subpopulation preferentially transmigrates across the BBB in response to chemokines, including CCL2 and CXCL12 [3, 8, 12, 13, 23, 24, 27] . Moreover, CXCL12 is elevated in the brains of HIV-infected people [29, 30] . We hypothesized that CXCR7 contributes to CD14 + CD16 + monocyte transmigration across the BBB to CXCL12 in HIV-infected individuals. This would result in neuroinflammation and neuronal damage that may lead to the development of HIVassociated cognitive deficits for which there currently are no therapies.
We first examined surface CXCR7 on monocytes from HIVinfected individuals. Their demographics and virological + CD16 + monocytes were pretreated with diluent or 10 mM CCX771 for 20 min before being added to the wells of a microchemotaxis chamber with a 5 mm polycarbonate membrane, as described in Materials and Methods. Cells chemotaxed to 5 ng/ml CXCL12 for 30 or 60 min at 37°C. Filters were then fixed and stained. Densitometry was used to determine the number of migrated cells per well, and fold change for each condition over baseline, which was set to 1 as indicated by the dotted line, was calculated for 8 independent experiments. The maximal chemotaxis to CXCL12 that was determined at 30 or 60 min for each independent experiment is presented and quantified. Data are represented as means 6 SEM. Significance was determined by Wilcoxon signed-rank test. Significance is compared with baseline unless indicated otherwise. *P , 0.05; **P , 0.01. 208.8; Fig. 5D ), which is similar to what we found for HIVnegative individuals (Fig. 2) . Although 31.6% of all subjects were ART naïve, we did not detect a difference in CXCR7 or CXCR4 between those that were ART naïve or those that were prescribed therapy (data not shown). However, in a direct comparison of our CXCR7 data between both monocyte subsets from HIVinfected individuals and HIV-negative people, we found that CXCR7 is significantly higher on both monocyte subsets from HIV-infected people compared with the expression on those cells from HIV-negative individuals (Supplemental Fig. 2 ).
CCX771 reduces transmigration across the BBB of CD14 + CD16 + monocytes from PBMC of HIV-infected people
To determine whether increased surface CXCR7 on CD14 + CD16 + monocytes from HIV-infected people compared with their CD14 + CD16 2 monocytes contributes to a functional difference between these 2 monocyte subsets, we used CCX771 to examine the role of CXCR7 in transmigration. All samples used for transmigration were from subjects that were on ART. We found that CXCL12 induced significant transmigration across the BBB for all cell types compared with baseline (Fig. 6) . CXCL12-mediated transmigration of CD14 + CD16 + monocytes was reduced significantly by CCX771. Unexpectedly, their transmigration was also reduced by AMD3100 (Fig. 6A) . In contrast, transmigration of CD14 + CD16 2 monocytes was not blocked by CCX771, but AMD3100 did significantly reduce their transmigration (Fig. 6B ). This suggests that CD14 + CD16 + monocytes from HIV-infected individuals use both CXCR7 and CXCR4 in the transmigration process, whereas CD14 + CD16 2 monocytes use CXCR4 only. T Cells were blocked significantly by AMD3100 to below baseline, whereas CCX771 also reduced their transmigration, but it remained significantly higher than baseline (Fig. 6C ). This may indicate that CXCR7, as was found with cells from HIV-negative individuals, may contribute to the transmigration of T cells to CXCL12 but that it is likely that their transmigration is mainly mediated by CXCR4.
DISCUSSION
Cognitive deficits as a result of HIV infection of the brain are mediated, in part, by entry of CD14 + CD16 + monocytes into the CNS [3, 13, 24, 59] . Although ART has significantly improved the lives of people with HIV, it has not decreased the incidence of HIV-associated neurocognitive disorders [5, 7] . In addition, there are still no therapies that decrease neuroinflammation and neurodegeneration mediated by HIV infection of the CNS. Whereas some therapeutic targets have been suggested, these do not prevent entry of CD14 + CD16 + monocytes specifically into the brain [23, [60] [61] [62] . We demonstrated in this study that CXCR7 is expressed on the cell surface of CD14 + CD16 + monocytes, that it is higher in expression on CD14 + CD16 + monocytes than on CD14 + CD16 2 monocytes, and that it is increased on the surface monocytes that could reduce the entry of this specific monocyte subset into the CNS. This would reduce the neuroinflammation potentially contributing to the cognitive deficits in HIV-infected people.
Monocytes are heterogeneous, and the subpopulations are classified based on their CD14 and CD16 expression [22, 26, 63, 64] . CD14 + CD16 + monocytes are increased in the peripheral blood during HIV infection and contribute to HIV infection of the CNS [12, 13, 23, 24] . We showed that CD14 + CD16
+ monocytes transmigrate to low levels of CXCL12 and transmigrate in significantly greater numbers relative to input across the BBB than do CD14 + CD16 2 monocytes or CD3 + T cells. This suggests that early after peripheral infection, even with low constitutive levels of CXCL12 in the brain, HIV-infected and uninfected CD14 + CD16 + monocytes may enter the CNS, leading to early viral seeding and initiation of neuroinflammation.
Transmigration to CXCL12 may be mediated by CXCR7 and CXCR4. CXCR4 has been established for decades as essential to cell movement, whereas CXCR7 was only shown in the past 10 yr to be important in the migration of certain cell types [32] [33] [34] . To determine whether CXCR7 could be involved, we examined its expression on both monocyte subsets. As the expression of CXCR7 on monocytes is controversial [41, 43, 44] , we used a directly fluorophore-coupled 11G8 antibody clone and showed with an antibody adsorption assay that this antibody is specific to CXCR7, as described previously [41] . We showed that CXCR7 is expressed on CD14 + CD16 + monocytes and found that CD14 + CD16 2 monocytes minimally express surface CXCR7. The conflicting results on CXCR7 from prior studies may be a result of the isolation method of the cells of interest. In 1 study, CD14 + monocytes isolated by magnetic beads did not express CXCR7 [41] . In our experiments, this method of isolation masked CXCR7 (data not shown), which may account for that negative finding. In other studies that did not use magnetic bead isolation, CXCR7 expression was found on the total monocyte population [43, 44] . The variations we showed in CXCR7 expression between CD14 + CD16 + monocytes and CD14 + CD16 2 monocytes may result in significant differences in their functional properties, supported by our finding that there is a difference in the CXCL12-mediated transmigration mechanisms of the 2 monocyte subsets. We determined that CXCR7 mediates the transmigration of CD14 + CD16 + monocytes to CXCL12 and that CXCR4 but not CXCR7 mediates the transmigration of CD14 + CD16 2 monocytes using a BBB model and antagonists for CXCR7 (CCX771) and CXCR4 (AMD3100). These antagonists specifically block their respective receptors and have been used to examine the function of each receptor in different physiologic processes. AMD3100 was examined in HIV-infected individuals as an antagonist to block interaction between HIV and its coreceptor CXCR4 [65, 66] . However, it failed to be approved as a result of its causing a large increase in WBC counts by mobilizing cells from the bone marrow. It now is in clinical use as Plerixafor to mobilize hematopoietic stem cells in individuals with cancer, with minor adverse effects reported [67] . CCX771 has not been tested yet in clinical trials, and its toxicity remains to be determined. Nevertheless, other studies showed the therapeutic potential of CCX771 for several different inflammatory diseases and cancer [31, 42, 58, 68] .
With the use of these antagonists in our study, we showed a distinct difference in the transmigration mechanism of CD14 pose less of a risk for development of progressive multifocal leukoencephalopathy, which occurred with rituximab therapy that reduced all immune surveillance and could possibly occur with use of natalizumab and other integrin inhibitors that do not specifically target 1 monocyte subset [61, 77, 78] . HIV infection remains a major problem worldwide, and with the success of ART, people with HIV are living longer. However, ART has led to an increased incidence of agerelated comorbidities at a younger age in HIV-infected people, including cognitive deficits [79] [80] [81] . In the current ART era, accelerated aging is commonly seen in individuals infected with HIV [80] . HIV infection is associated with increased early incidence of cardiovascular disease, cancer, neurocognitive deficits, and other comorbidities that may be mediated, in part, by chronic inflammation and immune activation defined as "inflammaging" [79] [80] [81] . Our characterization of CXCR7 on CD14 + CD16 + monocytes and our data on the reduction of CXCL12-mediated CD14 + CD16 + monocyte transmigration across the BBB in the presence of CCX771 suggest that CCX771 may limit the entry of HIVinfected and uninfected CD14 + CD16 + monocytes into the CNS, thereby reducing viral seeding, neuroinflammation, and neuronal damage that may ameliorate the cognitive deficits related to HIV. In addition, it may reduce CD14 + CD16 + monocyte transmigration into tissues in many other inflammatory diseases, including rheumatoid arthritis, diabetes, atherosclerosis, and stroke [45, 68, 75, 76, 82] . 
